This protocol isn't appropriate for patients who are pregnant or nursing, individuals under 18, those with active cancer, or patients with contraindications to GLP-1 medications (medullary thyroid carcinoma history, MEN2 syndrome, history of pancreatitis)
Furthermore, the newly available oral semaglutidethe first oral formulation of GLP-1 RA for the treatment of T2D [98]has shown efficacy, safety and tolerability in a number of studies [35, 44,45,46,47,48,49,50,51]
Start Losing Weight with GLP-1 Medication Today
Decreased blood flow results in shrinking of the prostate, reducing obstruction and relieving urinary symptoms
Wang D, Wei G, Ma J, Cheng S, Jia L, Song X, et al